Clinical Trials Directory

Trials / Completed

CompletedNCT01485679

18 Fluoro-deoxy-glucose Positrons Emission Tomography Combined With Computed Tomography (18-FDG TEP-CT ) in the Diagnosis of the Degeneration of Intraductal Papillary Mucinous Tumor of the Pancreas

Evaluation of 18 Fluoro-deoxy-glucose Positrons Emission Tomography Combined With Computed Tomography (18-FDG TEP-CT ) in the Diagnosis of the Degeneration of Intraductal Papillary Mucinous Tumor of the Pancreas

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
126 (actual)
Sponsor
Nantes University Hospital · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The aim of the study is to evaluate whether the TEP-CT can be sensitive and specific in identifying degenerated intraductal papillary mucinous tumor of the pancreas.The results will be compared to those obtained by the pathological analysis of the removed piece of pancreas.

Detailed description

Before surgery is undertaken, a 18 fluoro-deoxy-glucose positrons emission tomography combined with computed tomography (18-FDG TEP-CT ) will be performed. The primary outcome of this study is to compare results of the TEP-CT with those obtained by the pathological analysis of the removed piece of pancreas.

Conditions

Interventions

TypeNameDescription
OTHER18 fluoro-deoxy-glucose positrons emission tomography combined with computed tomography18 fluoro-deoxy-glucose positrons emission tomography combined with computed tomography

Timeline

Start date
2011-01-01
Primary completion
2015-04-01
Completion
2015-04-01
First posted
2011-12-05
Last updated
2016-05-18

Locations

12 sites across 1 country: France

Source: ClinicalTrials.gov record NCT01485679. Inclusion in this directory is not an endorsement.